Dublin, April 07, 2015 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/vzq5lk/her2_positive) has announced the addition of the "HER-2 Positive Breast Cancer Market in the US 2015-2019" report to their offering.
The HER-2 Positive Breast Cancer market in US to grow at a CAGR of 12.65% over the period 2014-2019
Breast cancer is characterized by uncontrolled growth of cancerous cells in the breast. It occurs in both males and females, however, the incidence of breast cancer in males is rare. Histologically, breast cancer can be classified into ductal carcinoma, lobular carcinoma, nipple cancer, and other undifferentiated carcinoma. Breast cancer is the second most common form of cancer in women. HER-2 is a protein that affects the growth of malignant cells and is usually found on the surface of normal breast cells. Sometimes, a large number of HER-2 receptors are found on the surface of breast cancer cells. These HER-2 receptors are responsible for stimulating the growth and division of malignant cancerous cells.
This condition is therefore known as HER-2 positive breast cancer. HER-2 positive breast cancers have a tendency to spread and metastasize more rapidly than HER-2 negative breast cancers. HER-2 positive breast cancer is more prevalent in females than males. In 2012, GLOBOCAN reported that breast cancer accounted for 11.9 percent of the total number of cancer cases and led to 522,000 deaths worldwide. HER-2 positive breast cancer accounts for almost 25 percent of all types of breast cancer.
One key trend upcoming in this market is the increase in awareness. Awareness and screening programs can help diagnose potential breast cancer cases, which might otherwise remain undetected till the last stage.
According to the report, the increase in prevalence of breast cancer is one of the major contributors to the growth of the market. A sedentary lifestyle coupled with increased urbanization and increased life expectancy raises the chance of developing diseases such as breast cancer.
Further, the report states that a primary challenge faced by this market is the poor diagnosis and screening rate for breast cancer. Diagnosis at a later stage limits the effectiveness of a treatment, despite its availability.
Key Vendors
- Celgene
- F. Hoffmann-La Roche
- GlaxoSmithKline
- Novartis
- Sanofi
Other Prominent Vendors
- Bristol-Myers Squibb
- DARA BioSciences
- Eisai
- Hospira
- Pfizer
- ProStrakan
- Sun Pharmaceutical Industries
- Teva Pharmaceutical
For more information visit http://www.researchandmarkets.com/research/vzq5lk/her2_positive